Context Total Assets from 2010 to 2024

CNTX Stock

USD 1.39 0.05 3.47%

Context Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

16.1 M

Current Value

22.7 M

Quarterly Volatility

18.2 M

Credit Downgrade

Yuan Drop

Covid

Check Context Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Context Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 435.1 K, Selling General Administrative of 9.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6. Context financial statements analysis is a perfect complement when working with Context Therapeutics Valuation or Volatility modules.

Check out the analysis of Context Therapeutics Correlation against competitors.

For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Latest Context Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Context Therapeutics over the last few years. Total assets refers to the total amount of Context Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Context Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Context Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Context Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 16.06 M

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Context Total Assets Regression Statistics

	Arithmetic Mean	24,360,283
	Geometric Mean	11,466,649
	Coefficient Of Variation	74.80
	Mean Deviation	11,270,379
	Median	24,006,000
	Standard Deviation	18,222,634
	Sample Variance	332.1T
	Range	68.1M
	R-Value	(0.02)
	Mean Square Error	357.5T
	R-Squared	0.0003
	Significance	0.95
	Slope	(70,648)
	Total Sum of Squares	4648.9T

Context Total Assets History

	2024	22.7 M
	2023	16.1 M
	2022	38 M
	2021	51.3 M
	2020	467.3 K
	2018	273.5 K
	2017	68.3 M

Other Fundumenentals of Context Therapeutics

Intangibles To Total Assets

Context Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Good Will	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Debt	Net Invested Capital	Capital Stock	Net Working Capital
Total Assets		0.98	-0.07	-0.51	-0.39	0.04	0.08	-0.69	0.32	-0.55	0.97	-0.6	0.08	0.57	-0.02	-0.32	0.46	0.26	0.33
Total Stockholder Equity	0.98		0.06	-0.54	-0.44	0.04	-0.06	-0.83	0.27	-0.61	0.97	-0.73	-0.06	0.71	0.0	-0.44	0.55	0.41	0.44
Net Tangible Assets	-0.07	0.06		0.48	-0.02	-0.76	-0.6	-0.33	-0.88	0.38	0.14	-0.03	-0.6	0.5	-0.7	-0.88	0.76	0.89	0.88
Retained Earnings	-0.51	-0.54	0.48		0.31	-0.59	0.18	0.45	-0.77	0.7	-0.39	0.62	0.18	-0.32	-0.56	-0.36	0.25	0.18	0.35
Accounts Payable	-0.39	-0.44	-0.02	0.31		-0.32	-0.01	0.44	-0.26	0.28	-0.37	0.35	-0.01	-0.41	-0.37	0.2	-0.42	-0.17	-0.22
Long Term Debt	0.04	0.04	-0.76	-0.59	-0.32		0.36	-0.08	0.91	-0.64	-0.17	-0.36	0.36	-0.07	0.99	0.61	-0.46	-0.58	-0.6
Good Will	0.08	-0.06	-0.6	0.18	-0.01	0.36		0.27	0.39	-0.11	-0.08	0.21	1.0	-0.32	0.27	0.35	-0.25	-0.49	-0.35
Total Liab	-0.69	-0.83	-0.33	0.45	0.44	-0.08	0.27		-0.12	0.68	-0.7	0.9	0.27	-0.94	-0.07	0.62	-0.64	-0.67	-0.62
Deferred Long Term Liab	0.32	0.27	-0.88	-0.77	-0.26	0.91	0.39	-0.12		-0.71	0.1	-0.4	0.39	-0.07	0.86	0.66	-0.5	-0.63	-0.66
Short Long Term Debt	-0.55	-0.61	0.38	0.7	0.28	-0.64	-0.11	0.68	-0.71		-0.41	0.91	-0.11	-0.44	-0.61	-0.05	0.04	0.06	0.05
Total Current Assets	0.97	0.97	0.14	-0.39	-0.37	-0.17	-0.08	-0.7	0.1	-0.41		-0.56	-0.08	0.61	-0.2	-0.49	0.6	0.42	0.5
Short Term Debt	-0.6	-0.73	-0.03	0.62	0.35	-0.36	0.21	0.9	-0.4	0.91	-0.56		0.21	-0.72	-0.36	0.32	-0.3	-0.34	-0.32
Intangible Assets	0.08	-0.06	-0.6	0.18	-0.01	0.36	1.0	0.27	0.39	-0.11	-0.08	0.21		-0.32	0.27	0.35	-0.25	-0.49	-0.35
Common Stock	0.57	0.71	0.5	-0.32	-0.41	-0.07	-0.32	-0.94	-0.07	-0.44	0.61	-0.72	-0.32		-0.08	-0.7	0.73	0.82	0.7
Property Plant Equipment	-0.02	0.0	-0.7	-0.56	-0.37	0.99	0.27	-0.07	0.86	-0.61	-0.2	-0.36	0.27	-0.08		0.57	-0.43	-0.55	-0.57
Net Debt	-0.32	-0.44	-0.88	-0.36	0.2	0.61	0.35	0.62	0.66	-0.05	-0.49	0.32	0.35	-0.7	0.57		-0.94	-0.92	-1.0
Net Invested Capital	0.46	0.55	0.76	0.25	-0.42	-0.46	-0.25	-0.64	-0.5	0.04	0.6	-0.3	-0.25	0.73	-0.43	-0.94		0.86	0.95
Capital Stock	0.26	0.41	0.89	0.18	-0.17	-0.58	-0.49	-0.67	-0.63	0.06	0.42	-0.34	-0.49	0.82	-0.55	-0.92	0.86		0.92
Net Working Capital	0.33	0.44	0.88	0.35	-0.22	-0.6	-0.35	-0.62	-0.66	0.05	0.5	-0.32	-0.35	0.7	-0.57	-1.0	0.95	0.92

Click cells to compare fundamentals

About Context Therapeutics Financial Statements

Context Therapeutics investors use historical fundamental indicators, such as Context Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Context Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	16.1 M	22.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC